DALLAS, December 1, 2014 /PRNewswire/ --
ReportsnReports.com adds EpiCast Report: Rheumatoid Arthritis - Epidemiology Forecast to 2023 market research on the autoimmune disease that causes inflammation of the joints. The research is spread across 48 pages and provides global and historical epidemiological trends for RA in the 10 major markets (10MM) (US, France, Germany, Italy, Spain, UK, Japan, Australia, China, and India). Complete report is available at http://www.reportsnreports.com/reports/319489-epicast-report-rheumatoid-arthritis-epidemiology-forecast-to-2023.html.
Epidemiologists forecast an increase in the total prevalent cases of Rheumatoid Arthritis (RA) in the 8MM, from 12,901,398 total prevalent cases in 2013 to 14,896,291 total prevalent cases in 2023, at an Annual Growth Rate (AGR) of 1.55% over the forecast period. They also forecast an increase in the diagnosed prevalent cases of RA in the 10MM, from 7,328,399 diagnosed prevalent cases in 2013 to 8,518,398 diagnosed prevalent cases in 2023, at an AGR of 1.62% over the forecast period.
For this analysis, the epidemiologists used country-specific data from peer-reviewed journals to construct the 10-year epidemiological forecast for the total prevalent cases of Rheumatoid Arthritis (RA) in the 8MM. They built the forecast for the diagnosed prevalent cases of RA in the 10MM using a combination of country-specific primary and secondary sources. A major strength of this epidemiological analysis is the use of consistent disease definitions and uniform diagnostic criteria, thereby allowing for a meaningful comparison of the epidemiological characteristics of RA in the 10MM.
The EpiCast Report: Rheumatoid Arthritis - Epidemiology Forecast to 2023, available for purchase at http://www.reportsnreports.com/Purchase.aspx?name=319489 , provide an overview of the risk factors, comorbidities, and the global and historical epidemiological trends for RA in the 10 major markets (10MM) (US, France, Germany, Italy, Spain, UK, Japan, Australia, China, and India). It also includes a 10-year epidemiological forecast for the total prevalent cases of RA, segmented by age (18 to =85 years) and sex in the eight major markets (8MM) (France, Germany, Italy, Spain, UK, Japan, China, and India). Additionally, this report includes a 10-year epidemiological forecast for the diagnosed prevalent cases of RA in the 10MM. The EpiCast Report is an in-depth, high quality, transparent and market-driven, providing expert analysis of disease trends in the 10MM. It is easy to navigate, interactive with dashboards, and epidemiology-based with transparent and consistent methodologies. Moreover, the model supports data presented in the report and showcases disease trends over a 10-year forecast period using reputable sources. The RA epidemiology report and model were written and developed by Masters- and PhD-level epidemiologists.
This Rheumatoid Arthritis (RA) market report helps develop business strategies by understanding the trends shaping and driving the global RA market as well as quantify patient populations in the global RA market to improve product design, pricing, and launch plans. It also helps organize sales and marketing efforts by identifying the sex and age groups that present the best opportunities for RA therapeutics in each of the markets covered.
On Rheumatoid Arthritis market, ReportsnReports.com offers following other research studies:
The Juvenile Rheumatoid Arthritis Global Clinical Trials Review, H2, 2014 research report provides elemental information and data relating to the clinical trials on Juvenile Rheumatoid Arthritis. It includes an overview of the trial numbers and their recruitment status as per the site of trial conduction across the globe. The databook offers a preliminary coverage of disease clinical trials by their phase, trial status, prominence of the sponsors and also provides briefing pertaining to the number of trials for the key drugs for treating Juvenile Rheumatoid Arthritis. Complete report is available at http://www.reportsnreports.com/reports/314266-juvenile-rheumatoid-arthritis-global-clinical-trials-review-h2-2014.html .
Advances in the Rheumatoid Arthritis Market 2014 research report forecasts that by 2018, the immunology market will be worth over US$38.5bn as leading players focus on growing their RA franchises in the emerging markets, launch innovative targeted synthetic DMARDs and biologic DMARDs to address unmet clinical needs and biosimilars emerge in the European market to carve out US$3bn share of revenues. This report examines in more detail the recent developments that have occurred in the RA market, including the expansion of approved products for new indications, formulations and new market launches and analyses the progression of pipeline products. It assesses how the new American College of Rheumatology (ACR) and European League against Rheumatism (EULAR) guidelines will impact product uptake and discusses the potential impact of biosimilars on the global RA market.
The Global Rheumatoid Arthritis Drugs market will grow at a CAGR of 4.09% to 2018 according to another research report. This report covers the present scenario and the growth prospects of the Global Rheumatoid Arthritis Drugs market for the period 2014-2018. To calculate the market size, the report considers the revenue generated from the sales of various drugs used in the treatment of RA that are available in the market. The Global Rheumatoid Arthritis Drugs market can be divided into two segments: Symptomatic and DMARDs. The Global Rheumatoid Arthritis Drugs Market 2014-2018 research report discusses companies like AbbVie Inc., Amgen Inc., Bristol-Myers Squibb Co., F. Hoffmann-La Roche Ltd., Janssen Pharmaceuticals Inc., Pfizer Inc., AB Science SA, Astellas Pharma Inc., AstraZeneca plc, Biogen Idec Inc., Boehringer Ingelheim GmbH, Celgene Corp., Daiichi Sankyo Co. Ltd., Eli Lilly & Co., GE Healthcare Co., Genmab A/S, GSK plc, Incyte Corp., Merck & Co. Inc., Mitsubishi Tanabe Pharma Corp., Novartis AG, Novo Nordisk A/S, Rigel Pharmaceuticals Inc., Sanofi, Takeda Pharmaceutical Co. Ltd., UCB SA and Vertex Pharmaceuticals Inc.
Explore more reports on the pharmaceuticals market at http://www.reportsnreports.com/market-research/pharmaceuticals/ .
ReportsnReports.com is an online market research reports library of 500,000+ in-depth studies of over 5000 micro markets. Not limited to any one industry, ReportsnReports.com offers research studies on agriculture, energy and power, chemicals, environment, medical devices, healthcare, food and beverages, water, advanced materials and much more.
TX, Dallas North - Dominion Plaza,
17304, Preston Road,
Suite 800, Dallas 75252
Connect With Us on:
Twitter: https: //twitter.com/marketsreports
G+ / Google Plus: https://plus.google.com/111656568937629536321/posts